Drug Approval | June 26, 2024
USDA approves Merck Animal Health’s NOBIVAC NXT canine flu H3N2
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated
